Companies in #Diabetic Macular Edema

Kodiak Sciences is a precommercial, retina-focused biotechnology company based in Palo Alto, California, built around its Antibody Biopolymer Conjugate (ABC) platform, which conjugates a humanised anti-VEGF antibody to a high-molecular-weight phosphorylcholine-based biopolymer through a single-site covalent linkage to extend durability of effect in the eye. Its lead medicine, Zenkuda (tarcocimab tedromer), reported positive topline results in the pivotal Phase 3 DAYBREAK study in wet age-related macular degeneration on September 28, 2026, meeting its primary endpoint at a p-value of 0.0007 with non-inferior vision gains versus aflibercept at year one and 54% of patients on six-month dosing durability, and now has a BLA-ready profile across five positive Phase 3 studies. The company plans a multi-indication Biologics License Application in the fourth quarter of 2026 spanning wet AMD, diabetic retinopathy and retinal vein occlusion, while its bispecific VEGF/IL-6 inhibitor tabirafusp alfa tedromer (KSI-501) is being evaluated in wet AMD and diabetic macular edema.

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.

Surrozen is a clinical-stage biotechnology company developing targeted antibodies that selectively modulate Wnt signalling, the pathway that governs stem-cell renewal, tissue structure and repair, with its current focus on sight-threatening ophthalmic disease. Its lead candidate, SZN-8141, is a bifunctional antibody that combines Frizzled 4 (FZD4)-mediated Wnt agonism with VEGF antagonism to address both vascular leakage and retinal vascular integrity; the company submitted an Investigational New Drug application for SZN-8141 in diabetic macular edema in September 2026 and expects to begin the DUET Phase 1b/2a study by year-end 2026, with initial data anticipated in the second half of 2027. The earlier SZN-043 programme, built on the company's SWEETS technology, is a Wnt agonist antibody developed for severe liver disease, initially severe alcohol-associated hepatitis, and has completed a Phase 1a study in chronic liver disease and healthy volunteers ahead of a Phase 1b multiple-ascending-dose trial.